title: Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
abstract: A new dysfibrinogenemia associated with thrombophilia has been identified in a Venezuelan kindred. Thrombin and Reptilase times were prolonged and the accelerating capacity of the patient's fibrin on the t-PA-induced plasminogen activation was decreased. In addition the affinity of fibrinogen for plasminogen was diminished. Permeability and electron microscopy studies revealed that the abnormal clot was made up of thin and densely packed fibres giving rise to a reduced fibrin gel porosity. This was confirmed by turbidity studies showing a decreased fibre mass/length ratio. Affected members were heterozygous for an Aalpha 532 Ser-->Cys mutation as demonstrated by genetic analyses. This abnormal fibrinogen has been designated as Fibrinogen Caracas V. The family study showed a convincing association between the mutation and thrombotic manifestations. The thrombotic tendency may be ascribed to lack of accelerating capacity of fibrin to induce fibrinolysis caused by an abnormal clot structure with thin fibres and reduced porosity.
authors.affiliation: Centro de Medicina Experimental, Laboratorio de Fisiopatología, Instituto Venezolano de Investigaciones Cientificas, IVIC, Caracas, Venezuela.
authors.forename: R
authors.initials: R
authors.lastname: Marchi
authors.forename: U
authors.initials: U
authors.lastname: Lundberg
authors.forename: J
authors.initials: J
authors.lastname: Grimbergen
authors.forename: J
authors.initials: J
authors.lastname: Koopman
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: N B
authors.initials: NB
authors.lastname: de Bosch
authors.forename: F
authors.initials: F
authors.lastname: Haverkate
authors.forename: C L
authors.initials: CL
authors.lastname: Arocha Piñango
mesh_terms: D000293:Adolescent; D000328:Adult; D019943:Amino Acid Substitution; D001777:Blood Coagulation / Q000235:genetics; D001780:Blood Coagulation Tests / Q000379:methods; D004252:DNA Mutational Analysis; D005192:Family Health; D005260:Female; D005337:Fibrin / Q000494:pharmacology / Q000648:ultrastructure; D015241:Fibrinogens, Abnormal / Q000235:genetics* / Q000378:metabolism / Q000648:ultrastructure; D006579:Heterozygote; D006801:Humans; D007457:Iodine Radioisotopes; D007700:Kinetics; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009391:Nephelometry and Turbidimetry; D010375:Pedigree; D010958:Plasminogen / Q000187:drug effects / Q000378:metabolism / Q000592:standards; D012008:Recurrence; D017422:Sequence Analysis, DNA; D019851:Thrombophilia / Q000209:etiology / Q000235:genetics; D013927:Thrombosis / Q000209:etiology* / Q000235:genetics; D010959:Tissue Plasminogen Activator / Q000494:pharmacology
chemical_list: D015241:Fibrinogens, Abnormal; D007457:Iodine Radioisotopes; C418193:fibrinogen Caracas V; D005337:Fibrin; D010958:Plasminogen; D010959:Tissue Plasminogen Activator